Evidence map›Paper›PMID 40179831›Full record

ReviewNeuroimmunomodulation2025

The Metabolomic Mind: Microbial Metabolite Programming of Microglia.

Branden G Verosky, Michael T Bailey, Tamar L Gur

Abstract readReview
In one paragraph

Review in Neuroimmunomodulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Branden G VeroskyMedical Scientist Training Program, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Michael T BaileyDepartment of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Tamar L GurDepartment of Neuroscience, College of Medicine, The Ohio State University, Columbus, Ohio, USA.

Funding

Prenatal neuroinflammation: maternal microbiome contributions and behavioral consequencesR01MH129589 · NIMH · OHIO STATE UNIVERSITY · PI Tamar Gur · 2022 to 2026
$2.8M
A novel live biologic for the prevention and treatment of NEC-induced neurodevelopmental impairmentR01HD116839 · NICHD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GAIL E BESNER, Michael T Bailey · 2024 to 2026
$2.0M
Orchestrating tryptophan metabolites to protect neurodevelopment from prenatal stressR01MH134121 · NIMH · OHIO STATE UNIVERSITY · PI GUR, TAMAR · 2024 to 2024
$735k
NICHD NIH HHS R01 HD116839NIMH NIH HHS R01 MH129589NIMH NIH HHS R01 MH134121
6 · The paper itself

Abstract

backgroundThe gut microbiota is increasingly recognized as a critical regulator of brain function, influencing neurodevelopment, brain physiology, and disease vulnerability in part through its interactions with microglia, the resident immune cells of the central nervous system. Microbial metabolites, beginning prenatally and persisting throughout the lifespan, modulate fundamental aspects of microglial biology. SUMMARY: Microglia from germ-free mice exhibit persistent immaturity, altered energy metabolism, and blunted inflammatory responses, which can be partially reversed by microbial colonization or supplementation with specific bacterial metabolites. Short-chain fatty acids, tryptophan-derived indoles, and secondary bile acids have emerged as key microbial mediators that regulate microglial development, metabolism, and immune function, whereas certain inflammatory metabolites, such as trimethylamine <sc>n</sc>-oxide, disrupt microglial homeostasis, and worsen neurodegeneration. KEY MESSAGES: These findings reveal distinct metabolite-driven pathways linking microbial composition to microglial phenotypes, positioning the microbiome as a potential key influencer of neurodevelopmental trajectories and the pathophysiology of psychiatric and neurological disorders. Despite recent advances, major knowledge gaps persist in understanding the precise molecular intermediaries and mechanisms through which metabolite signaling to microglia shapes susceptibility or resilience to brain-based disorders. Understanding both the bacterial metabolomic landscape and its collective impact on microglial programming holds substantial therapeutic promise, offering avenues to target microbial metabolite production or administer them directly to modulate disease susceptibility.

Indexed as

BrainGastrointestinal MicrobiomeMicrogliaAnimalsHumansMetabolomicsMiceGut-brain axisMicrobiomeMicrogliaShort-chain fatty acidsTrimethylamine oxideTryptophan

Identifiers

PMID40179831
PMCPMC12377074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.